Last reviewed · How we verify
V114 0.5x:0.5x:2x
V114 0.5x:0.5x:2x is a Biologic drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 1 development.
At a glance
| Generic name | V114 0.5x:0.5x:2x |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V114 0.5x:0.5x:2x CI brief — competitive landscape report
- V114 0.5x:0.5x:2x updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about V114 0.5x:0.5x:2x
What is V114 0.5x:0.5x:2x?
V114 0.5x:0.5x:2x is a Biologic drug developed by Merck Sharp & Dohme LLC.
Who makes V114 0.5x:0.5x:2x?
V114 0.5x:0.5x:2x is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).
What development phase is V114 0.5x:0.5x:2x in?
V114 0.5x:0.5x:2x is in Phase 1.
Related
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Compare: V114 0.5x:0.5x:2x vs similar drugs
- Pricing: V114 0.5x:0.5x:2x cost, discount & access